Pfizer Drops $225M Up-Front for Dimebon

After Medivation released its excellent phase IIb results at the Alzheimer’s conference in July, we all knew it was just a matter of time before they partnered the 30+ year old, Russian marketed anti-histamine for the treatment of Alzheimer’s and Huntington’s disease.
That time has come.
Terms:
- $225M up-front
- $500M in milestones
- 60/40 Pfizer/Medivation development cost [...]

Myriad Cancels Flurizan Development

One month after licensing EU rights to Lundbeck for $100M upfront (a deal I crapped on by the way), Myriad has discontinued the development of Flurizan for treating Alzheimer’s disease. Surprised? Not me.
As I’ve noted before (in multiple places), I’m not a fan of gamma-secretase modulators for AD. Every trial run so far [...]

Bapineuzumab Fails Trial

Image via Wikipedia

For a drug expected to top $7B in annual sales, even a partial success looks like a failure to me.  I’ve talked about the efficacy in modulating APP for the treatment of Alzheimer’s a few times and Derek Lowe @ has some great articles, so if you’re not familiar, I‘d check them out [...]